HYDERABAD: A New Era in Pharmaceutical Innovation

The National Company Law Tribunal has officially sanctioned the amalgamation of Suven Pharmaceuticals Ltd and Cohance Lifesciences Ltd, marking a significant milestone in the pharmaceutical industry. This merger, expected to be completed by the first quarter of the financial year 2025-26, is set to create a diversified CDMO platform with a strong focus on high-growth verticals such as antibody drug conjugates (ADCs), oligonucleotides, and small molecules.

Creating a Global Powerhouse

The combined entity aims to operate as an integrated, end-to-end partner to global innovator pharmaceutical companies, leveraging strong capabilities in specialty CDMO and API+ business segments. This strategic move is anticipated to enhance scale, broaden customer offerings, and drive operational synergies, fueling long-term growth and innovation.

Leadership's Vision for the Future

Vivek Sharma, Executive Chairman of Suven Pharma, highlighted the merger as a transformative phase that positions the company to become a $1 billion revenue entity within five years. Dr. V Prasada Raju, Managing Director, emphasized the merger's role in building a differentiated, innovation-led CDMO platform from India, ready to tackle the future of pharmaceutical innovation.